Sterling Capital Management’s 10x Genomics TXG Stock Holding History

Sterling Capital Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.1K	Sell	419 -2,554	-86%	-$66.9K	﹤0.01%	1982
2026 Q1	$63.1K	Sell	2,973 -1,916	-39%	-$38.3K	﹤0.01%	1546
2025 Q4	$79.7K	Sell	4,889 -648	-12%	-$9.79K	﹤0.01%	1623
2025 Q3	$64.7K	Buy	5,537 +3,363	+155%	+$43.8K	﹤0.01%	1678
2025 Q2	$25.2K	Sell	2,174 -2	-0.1%	-$18	﹤0.01%	1706
2025 Q1	$19K	Sell	2,176 -1,010	-32%	-$12.7K	﹤0.01%	1671
2024 Q4	$45.8K	Buy	3,186 +745	+31%	+$11.8K	﹤0.01%	1637
2024 Q3	$55.1K	Buy	+2,441	New	+$50.5K	﹤0.01%	1441

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sterling Capital Management's TXG Position: Q2 2026 in Review

Sterling Capital Management reduced its 10x Genomics (TXG) stake by 86% in Q2 2026, selling an estimated $66.9K and leaving 419 shares worth $16.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1982.

Sterling Capital Management first reported a position in TXG in Q3 2024 and has held it in 8 quarters since. The position peaked at $79.7K in Q4 2025. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Sterling Capital Management held 419 shares of 10x Genomics worth $16.1K as of Q2 2026.
Sterling Capital Management sold 2,554 10x Genomics shares in Q2 2026, an estimated $66.9K.
10x Genomics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1982 holding.
Sterling Capital Management first reported a position in 10x Genomics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's 10x Genomics position peaked at $79.7K in Q4 2025.
390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.